Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Significant Growth in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 29,926 shares, a growth of 49.7% from the July 15th total of 19,996 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 45,467 shares, the short-interest ratio is presently 0.7 days.

Redhill Biopharma Trading Down 1.5%

Shares of RDHL stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.58. The stock had a trading volume of 9,213 shares, compared to its average volume of 277,672. The firm has a market capitalization of $3.50 million, a PE ratio of 0.00 and a beta of 5.00. The stock’s 50-day moving average price is $0.73 and its two-hundred day moving average price is $0.87. Redhill Biopharma has a 52-week low of $0.58 and a 52-week high of $2.79.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Redhill Biopharma in a research note on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP bought a new position in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma makes up approximately 0.3% of Yorkville Advisors Global LP’s portfolio, making the stock its 19th biggest holding. Yorkville Advisors Global LP owned 7.57% of Redhill Biopharma at the end of the most recent quarter. Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.